ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
CoronaVirus Disease-2019 (COVID-19)
Conditions
CoronaVirus Disease-2019 (COVID-19)
Trial Timeline
Dec 10, 2020 → Aug 24, 2021
NCT ID
NCT04644120About ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04
ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04 is a phase 1 stage product being developed by AbbVie for CoronaVirus Disease-2019 (COVID-19). The current trial status is completed. This product is registered under clinical trial identifier NCT04644120. Target conditions include CoronaVirus Disease-2019 (COVID-19).
What happened to similar drugs?
0 of 12 similar drugs in CoronaVirus Disease-2019 (COVID-19) were approved
Approved (0) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04644120 | Phase 1 | Completed |
Competing Products
20 competing products in CoronaVirus Disease-2019 (COVID-19)